In vitro susceptibility of viridans group streptococci isolated from blood in southwest Finland in 1993–2004

References

• Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of beta-haemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000). Diagn Microbiol Infect Dis 2002; 43: 157–62
   PubMed Web of Science ®Google Scholar
• Rodriguez-Avial I, Rodriguez-Avial C, Culebras E, Picazo JJ. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans group streptococci harbouring erm(B) and mef(A) genes. Susceptibility to quinupristin/dalfopristin and linezolid. Int J Antimicrob Agents 2003; 21: 536–41
   PubMedGoogle Scholar
• Ioannidou S, Papaparaskevas J, Tassios PT, Foustoukou M, Legakis NJ, Vatopoulos AC. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in viridans group streptococci. Int J Antimicrob Agents 2003; 22: 626–9
   PubMedGoogle Scholar
• Rodriguez-Avial I, Rodriguez-Avial C, Culebras E, Picazo JJ. In vitro activity of telithromycin against viridans group streptococci and Streptococcus bovis isolated from blood: antimicrobial susceptibility patterns in different groups of species. Antimicrob Agents Chemother 2005; 49: 820–3
   PubMedGoogle Scholar
• Lyytikainen O, Rautio M, Carlson P, Anttila VJ, Vuento R, Sarkkinen H, et al. Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance. J Antimicrob Chemother 2004; 53: 631–4
   PubMed Web of Science ®Google Scholar
• Alcaide F, Benitez MA, Carratala J, Gudiol F, Linares J, Martin R. In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of 8 other antibiotics against viridans group streptococci isolated from blood of neutropenic patients with cancer. Antimicrob Agents Chemother 2001; 45: 624–6
   PubMedGoogle Scholar
• Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?. J Antimicrob Chemother 2000; 46: 347–50
   PubMed Web of Science ®Google Scholar
• Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001; 47: 77–81
   PubMed Web of Science ®Google Scholar
• Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Programme. Ann Pharmacother 2003; 37: 769–74
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251–5
   PubMed Web of Science ®Google Scholar
• Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005; 40: 1657–64
   PubMed Web of Science ®Google Scholar
• CLSI, Performance Standards for Antimicrobial Susceptibility testing; fifteenth Informational Supplement M100-S15. Vol. 24. 2005, Wayne, PAUSA: Clinical and Laboratory Standards Institute.
   Google Scholar
• Rantala M, Haanpera-Heikkinen M, Lindgren M, Seppala H, Huovinen P, Jalava J. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob Agents Chemother 2006; 50: 1855–8
   PubMed Web of Science ®Google Scholar
• Seppala H, Haanpera M, Al-Juhaish M, Jarvinen H, Jalava J, Huovinen P. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 2003; 52: 636–44
   PubMed Web of Science ®Google Scholar
• Figueira-Coelho J, Ramirez M, Salgado MJ, Melo-Cristino J. Streptococcus agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, serotype distribution, and clonal analysis of macrolide-resistant isolates. Microb Drug Resist 2004; 10: 31–6
   PubMed Web of Science ®Google Scholar
• Rantala M, Huikko S, Huovinen P, Jalava J. Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002. Antimicrob Agents Chemother 2005; 49: 4180–4
   PubMed Web of Science ®Google Scholar
• Alcaide F, Linares J, Pallares R, Carratala J, Benitez MA, Gudiol F, et al. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995; 39: 2243–7
   PubMedGoogle Scholar
• Ardanuy C, Tubau F, Linares J, Dominguez MA, Pallares R, Martin R. Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes. Antimicrob Agents Chemother 2005; 49: 827–9
   PubMed Web of Science ®Google Scholar
• Jones RN, Pfaller MA. Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Programme (1997 to 1999): beyond Canada!. Antimicrob Agents Chemother 2000; 44: 2922–3
   PubMedGoogle Scholar
• Kennedy HF, Gemmell CG, Bagg J, Gibson BE, Michie JR. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother 2001; 47: 693–6
   PubMed Web of Science ®Google Scholar
• Marron A, Carratala J, Alcaide F, Fernandez-Sevilla A, Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 2001; 47: 87–91
   PubMed Web of Science ®Google Scholar
• Han XY, Kamana M, Rolston KV. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiological analysis of 50 cases. J Clin Microbiol 2006; 44: 160–5
   PubMedGoogle Scholar
• Uh Y, Shin DH, Jang IH, Hwang GY, Lee MK, Yoon KJ, et al. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from blood cultures in Korea. J Antimicrob Chemother 2004; 53: 1095–7
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect 2001; 7: 152–7
   PubMedGoogle Scholar
• Kataja J, Huovinen P, Skurnik M, Seppala H. Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob Agents Chemother 1999; 43: 48–52
   PubMed Web of Science ®Google Scholar
• Anderegg TR, Biedenbach DJ, Jones RN. In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci. J Antimicrob Chemother 2002; 49: 1019–21
   PubMedGoogle Scholar
• Tuohy M, Washington JA. Antimicrobial susceptibility of viridans group streptococci. Diagn Microbiol Infect Dis 1997; 29: 277–80
   PubMed Web of Science ®Google Scholar
• Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000; 44: 3374–80
   PubMed Web of Science ®Google Scholar
• Ergin A, Ercis S, Hascelik G. Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures. J Antimicrob Chemother 2006; 57: 139–41
   PubMed Web of Science ®Google Scholar
• Gershon AS, de Azavedo JC, McGeer A, Ostrowska KI, Church D, Hoban DJ, et al. Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000. Antimicrob Agents Chemother 2002; 46: 1553–6
   PubMedGoogle Scholar